Latest filing published 03 Nov 2026 for ELI LILLY & Co.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +89.4%Entry US$559.80 · Close at T+365 US$1,060.00
- +17.6%Entry US$111.67 · Close at T+365 US$131.31
- +30.5%Entry US$86.88 · Close at T+365 US$113.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Daniel Skovronsky: trading record in brief
This profile gathers the share dealings of Daniel Skovronsky across 2 companies, led by ELI LILLY & Co and Myriad Genetics Inc. The record holds 37 filings, for trades running from 14 June 2018 to 2 November 2026.
Both buying and selling appear: 3 purchases worth €1.8M, against 3 sales worth €4.2M. Netting one side against the other leaves €2.4M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 20 share grants and 5 option exercises.
The median purchase comes to €543k. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 100% of cases; the median change was +23.9%. This is a record of the past, not a forecast.
On 3 November 2026 came the latest disclosure, a transaction in ELI LILLY & Co. The most recent open-market purchase was published on 12 August 2025, 453 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Daniel Skovronsky
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 119 shares0Common StockSEC:0001741474-26-000006:0
- 15,547.862 shares@ US$1,044.6737.0% of flowCommon StockSEC:0001741474-26-000004:0
- 5,641.25 shares@ US$1,037.156.3% of flowCommon StockSEC:0001741474-26-000002:1
- 12,684 shares0Common StockSEC:0001741474-26-000002:0
- 179 shares0Common StockSEC:0001741474-25-000006:0
- 1,000 shares@ US$634.4051.5% of flowCommon StockSEC:0000059478-25-000214:0Canonical exit: 10 Nov 2025 (T+90)
- 49,796 shares0Common StockSEC:0001628280-25-029971:0
- 340 shares@ US$863.970.4% of flowCommon StockSEC:0000059478-25-000039:1
- 710 shares@ US$865.760.8% of flowCommon StockSEC:0000059478-25-000039:2
- 18,771.75 shares@ US$868.8820.4% of flowCommon StockSEC:0000059478-25-000039:3
- 3,950 shares@ US$862.698.9% of flowCommon StockSEC:0000059478-25-000039:0
- 4,003.64 shares@ US$811.084.0% of flowCommon StockSEC:0000059478-25-000028:1
- 8,989 shares0Common StockSEC:0000059478-25-000028:0
- 5,724 shares0Common StockSEC:0000059478-24-000215:1
- 111 shares0Common StockSEC:0000059478-24-000215:0
- 15,695 shares0Common StockSEC:0001628280-24-027520:0
- 12,910 shares@ US$737.2623.7% of flowCommon StockSEC:0000059478-24-000052:0
- 4,434 shares@ US$645.613.4% of flowCommon StockSEC:0000059478-24-000019:1
- 9,941 shares0Common StockSEC:0000059478-24-000019:0
- 17 shares0Common StockSEC:0000059478-23-000290:0
- 249 shares0Common StockSEC:0000059478-23-000225:0
- 15,151 shares0Common StockSEC:0001628280-23-020713:0
- 18,388 shares@ US$345.1215.9% of flowCommon StockSEC:0000059478-23-000063:0
- 7,035 shares@ US$344.152.9% of flowCommon StockSEC:0000059478-23-000041:1
- 15,675 shares0Common StockSEC:0000059478-23-000041:0
25 of 37 declarations
